0
Détail de l'éditeur
|
|
Documents disponibles chez cet éditeur (4)
Ajouter le résultat dans votre panier Affiner la recherche
Titre : Artificial sweeteners in US-marketed oral nicotine pouch products : correlation with nicotine contents and effects on product preference Type de document : document électronique Auteurs : Sairam, V. Jabba, Auteur ; Peter Silinski, Auteur ; Alicia, Y. Yang, Auteur ; Wenyi Ouyang, Auteur ; Sven, E. Jordt, Auteur Editeur : National Institutes of Health (NIH) Année de publication : 2024-01 Importance : p. 263-367 Présentation : tab., graph Langues : Anglais (eng) Catégories : [DIVERS] géographie:Amérique:Amérique du Nord:Etats-Unis
[TABAC] chimie du tabac:constituant:alcaloïde:nicotineMots-clés : édulcorant - choix du produit (préférence) Index. décimale : TA 1.2 Tabac non fumé Résumé : Introduction:
Artificial sweeteners are listed as ingredients of oral nicotine pouches (ONPs), a new product category with rapidly growing market share. The exact sweetener contents of ONPs remain unknown. Artificial sweeteners in ONPs may facilitate initiation and encourage consumption behavior.
Aims and Methods:
Artificial sweetener contents in major US-marketed ONP brands (Zyn, on!, Velo) were determined by Liquid Chromatography-Mass Spectrometry (LC-MS). Sweetener effects during the initiation of ONP consumption were modeled in single- and two-bottle tests, offering mice ONP extracts calibrated to contain nicotine levels similar to saliva of people who use smokeless tobacco. To examine the contribution of sweet taste perception, consumption behavior was compared between wild-type mice and mice deficient in the sweet taste receptor (Tas1r2-/-).
Results:
Acesulfame-K was detected in on!, Zyn and Velo ONPs (~0.3-0.9 mg/pouch), including products marketed as “Unflavored” or “Flavor ban approved”. In Velo ONPs, sweetened with sucralose (0.6-1.2 mg/pouch), higher nicotine strength products contained higher sucralose levels. Tas1r2-/- mice consumed less ONP extracts than wild-type mice in both sexes. ONP extracts with both higher nicotine and sweetener strengths were tolerated by wildtype mice, but produced stronger aversion in Tas1r2-/- mice.
Conclusions:
ONPs contain significant amounts of artificial sweeteners, with some brands adding more sweetener to ONPs with higher nicotine strengths. Artificial sweeteners, at levels present in ONPs, increase nicotine consumption. Increasing sweetener contents facilitates consumption of ONPs with higher nicotine strengths. Sweetness is a key determinant of ONP use initiation, likely reducing the aversive sensory effects of nicotine and other ONP constituents.
Implications:
Artificial sweeteners such as acesulfame-K or sucralose reduce aversion and facilitate initiation and continued consumption of ONPs. The marketing of some artificially sweetened ONPs as
“Unflavored” of “Flavor ban-approved” suggests that the tobacco industry rejects sweet taste as a determinant for the presence of a characterizing flavor. Sweetness as imparted by artificial
sweeteners in tobacco products needs to be addressed by regulators as a component of a characterizing flavor, with the aim to reduce product appeal and initiation by never users, and
especially youth attracted to sweet flavors.Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10190 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Clusters of genetic variants linked to distinct treatment responses for smoking cessation / Dorie Hightower (02/06/2008)
Titre : Clusters of genetic variants linked to distinct treatment responses for smoking cessation Type de document : texte imprimé Auteurs : Dorie Hightower, Auteur Editeur : National Institutes of Health (NIH) Année de publication : 02/06/2008 Collection : NIH News Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique
[TABAC] tabagisme:risque:facteur associé:génétiqueIndex. décimale : TA 4.1.1 Facteurs prédictifs du tabagisme (génétique inclus) Résumé : Findigs may help to match smokers with treatments most likely to help them quit En ligne : https://www.nih.gov/news-events/news-releases/clusters-genetic-variants-linked-d [...] Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2845 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Smoking outcome by psychiatric history after behavioral and varenicline treatment Type de document : texte imprimé Auteurs : Jennifer B. McClure, Auteur ; Gary E. Swan, Auteur ; Sheryl L. Catz, Auteur ; Lisa Jack, Auteur Editeur : National Institutes of Health (NIH) Année de publication : 2010 Collection : NIH News num. 38:4 Importance : p. 394-402 Présentation : tab. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique
[TABAC] sevrage tabagique:effet du sevrage:anxiété
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:effet secondaire
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche psychologique
[TABAC] tabagisme:aspect psychologique:comportement
[TABAC] tabagisme:effet du tabac:effet psychiatrique:dépressionIndex. décimale : TA 6.1 Généralités Résumé : Treatment outcomes were compared across smokers enrolled in the COMPASS cessation trial with (PH+, n = 271) and without (PH-, n = 271) a diagnosis of psychiatric history based on medical record evidence of anxiety, depression, psychotic disorder, or bipolar disorder Everyone received behavioral counseling plus varenicline and was followed for 6 months post-quit date. PH+ smokers took varenicline for fewer days on average (59.4 vs. 68.5, P ≤ .01), but did not differ in their use of behavioral treatment. PH+ smokers were more likely to report anxiety and depression, but side-effect intensity ratings did not differ after adjusting for multiple comparisons. Overall, all side-effects were rated as moderate intensity or less. Groups had similar 30 day abstinence rates at 6 months (31.5% PH+ vs. 35.4% PH-, P = .35). In sum, having a psychiatric diagnosis in this trial did not predict worse treatment outcome or worse treatment side-effects. En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860053/ Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8099 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Treatment of smokers with co-occurring disorders : emphasis on integration in mental health and addiction treatment settings Type de document : texte imprimé Auteurs : Sharon M. Hall, Auteur ; Judith J. Prochaska, Auteur Editeur : National Institutes of Health (NIH) Année de publication : 2009 Collection : NIH News num. 5 Importance : p. 409-431 Langues : Anglais (eng) Catégories : [TABAC] prévention:santé:santé mentale
[TABAC] tabagisme:aspect psychologique:comportement:addiction:traitement des addictionsIndex. décimale : TA 6.1 Généralités Résumé : This article reviews the research on the treatment of cigarette smoking in individuals who have comorbid mental illnesses or non-nicotinic addictions. The prevalence of smoking in mentally ill and substance-abusing populations is presented, as well as reasons for this high prevalence. The historical role of cigarettes and tobacco in mental illness and addiction is reviewed to help the reader better understand the pervasiveness of smoking in these disorders and the relative absence of intervention efforts in mental heath and addiction treatment settings. The article then discusses the several reasons for integrating smoking treatment into mental health and addiction settings. The outcome research for adult and adolescent comorbid smokers is reviewed, and barriers to treatment are discussed. The review closes with a brief discussion of models of integration and thoughts about prevention. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8097 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005646 TA 6.1 HAL T Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
